Provided is tunable biopolymer hydrogel produced from two processed natural polysaccharides for use as a hemostat. If desired, the hydrogel formation can be tuned so that the hydrogel forms within seconds when applied to a tissue lesion. The resulting hydrogel can adhere to tissue and, without swelling, produce hemostasis within seconds after application to tissue of interest. The hydrogel also captures, aggregates and concentrates platelets and red blood cells at the site of the tissue lesion thereby initiating a clotting cascade at the site of the lesion. The hemostat can be used to prevent blood loss during surgical procedures, for example, during brain, spine or other surgical procedures where hemostasis is desirable, and is particularly useful during surgical procedures where swelling of the hemostat (e.g., in the brain or spine) would be detrimental to the subject.

A method is described. The method includes mixing fibrin and collagen to form a mixture including collagen and fibrin; and reducing the salt concentration below the threshold concentration to form a fibrin. A collagen-fibrin composition is also described. The composition includes a collagen and a fibrin; wherein the composition has a salt concentration below the threshold concentration to form a fibrin.

A silicone foam is described that is produced in-situ at a wound site, e.g. in a wound cavity, through a multi-component system, based on a physical foaming process, wherein the gas required to form the foam structure is provided through a blowing agent independently of the curing reaction of polyorganosiloxane components of the multi-component system. Therefore, the blowing agent is provided as a distinct entity of the multi-component system that is, in particular, not the result of any chemical reaction taking place in the multi-component system. A device for producing the foam and the corresponding negative pressure wound therapy kit are also described.

The present invention provides a pharmaceutical formulation comprising LL-37 or a pharmaceutically-acceptable salt thereof and one or more pharmaceutically-acceptable diluent or carrier system, for use in a method of treatment of a chronic ulcer wound (such as a hard-to-heal venous leg ulcer or a diabetic foot ulcer), which method comprises: (a) topical application of the formulation to the ulcer; followed by (b) application of a dressing, and wherein the application of the formulation provides for a dose of LL-37 at the wound site that is below about 80 g of LL-37 applied per cm2 of wound area, and/or below about 26.7 g of LL-37 applied per cm2 of wound area, per day of treatment.

The present disclosure provides a coacervate composition containing a protein drug, gelatin A, sodium alginate and an acid and a wound-healing agent including the same. The coacervate composition according to the present disclosure can be useful as a wound-healing material delivery system for effectively delivering a protein drug, particularly epidermal growth factor, to a wound site in the wound-healing field.

The present disclosure provides amine-modified polymer foams, which may be used for wound dressing materials. For example, the modified materials can include a covalently attached molecule comprising free amine groups. Such amine groups can be used, for instance, to conjugate biologically active polypeptides and/or linkers. Methods for using modified polymers are also provided.

Methods to produce substantially closed cell foams with densities less than 0.75 g/cm.sup.3, and more preferably less than 0.5 g/cm.sup.3, without substantial loss of the polymer's weight average molecular weight, have been developed. The closed cells foams have an open cell content of generally less than 50%, and more preferably an open cell content of less than 20%, and the cells have a maximum diameter of less than 5 mm. The foam may include poly-4-hydroxybutyrate or a copolymer thereof. Preferably, the foam is derived by heating a foam polymer formula to a temperature above the melt temperature of the polymer to form a melt polymer system, adding a blowing agent to produce a foamable melt, extruding the foamable melt through a die to a lower pressure to cause foaming, cooling of the foam, and solidification of the foam. These foam structures can be used for fabrication of medical products.

Novel compositions for treating wounds and promoting the healing thereof are described, including composition containing novel combinations of a carrier and recombinant platelet derived growth factor having fewer isoforms and enhanced biostability. Methods of treating wounds with novel therapeutic composition using doing procedures leading to effective results with a minimal number of treatment applications are also described.

An improvement to the effectiveness or take of skin grafts or tissue replacements used to treat wounds is provided. A therapeutic composition comprising recombinant human platelet-derived growth factor BB homodimer (rhPDGF-BB) and a porous biocompatible carrier is first applied to the wound surface, followed by applying a skin substitute or tissue replacements composition.

A dressing including a top film, an adhesive layer positioned adjacent the top film closer to a user's skin when the bandage is in use, a hydrogel layer including a support layer, below the adhesive layer closer to the user's skin when the bandage is in use, and a lower perforated layer positioned under the hydrogel layer for adhering the bandage to a user's skin. All of the layers may be transparent or at least partially translucent to allow a user to view the user's skin through the bandage. The hydrogel layer provides pressure distribution to reduce stress on the user's skin and reduce the likelihood of pressure ulcers.